NEW YORK (GenomeWeb) – Illumina plans to acquire Pacific Biosciences for approximately $1.2 billion in cash, the companies said on Thursday.

Under the agreement, which has been approved by both companies' boards of directors, Illumina will pay $8.00 per PacBio share, representing a 71 percent premium over PacBio's 30 trading-day volume weighted average share price as of the market close on Oct. 31, and a total value of about $1.2 billion on a fully diluted basis.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

John Mendelsohn, a former president of the University of Texas MD Anderson Cancer Center, has died, the New York Times reports.

Chinese state news agency Xinhua reports that a preliminary investigation has found He Jiankui performed his gene-editing work illegally.

Identical twins receive different estimates of ancestry from the same direct-to-consumer genetic testing firms, CBC reports.

In PNAS this week: chromosomal features of maize, adaptations in the vinous-throated parrotbill, and more.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
31
Sponsored by
Roche

This webinar highlights the use of single-cell genomics to identify distinct cell types and states associated with enhanced immunity.

Feb
14
Sponsored by
Oxford Nanopore Technologies

This webinar will describe a project that applied Oxford Nanopore long-read RNA-seq to explore the transcriptional landscape of a damaging agricultural pest.

Feb
19
Sponsored by
Pillar Biosciences

This webinar will demonstrate how clinical laboratories can develop their own customized targeted next-generation sequencing (NGS)-based solid tumor panels.